

Prostate Cancer Committee meeting

Date: 10/07/2018 – 11/07/2018

Location: NICE offices, London

Minutes: Final

NICE National Institute for
Health and Care Excellence

Committee members present:		
	Day 1	Day 2
Waqar Shah (WS) (Chair)	Present for all	Present for all
Pauline Bagnall (PB)	Present for all	Present for all
Guy Chetiyawardana (GC)	Present for all	Apologies
Charles Frost (CF)	Present for all	Present for all
John Graham (JG)	Present for all	Present for all
Sadaf Haque (SH)	Apologies	Present for all
Peter Jenkins (PJ)	Present for all	Present for all
Howard Kynaston (HK)	Present for all	Present for all
Sanjeev Madaan (SM)	Present for all	Present for all
Jon Oxley (JO)	Present for all	Present for all
Jonathan Richenberg (JR)	Present for all	Present for all
Karen Stalbow (KS)	Present for all	Present for all

In attendance:		
	Day 1	Day 2
Jean Bennie (JB) GUT – Technical Analyst	Present for all	Present for all
Chris Carmona (CC) GUT – Senior Technical Analyst	Present for all	Present for all
Clare Dadswell (CD) GUT – Technical Analyst	Present for all	Apologies
Rupert Franklin (RF) NICE – Senior Guidelines Commissioning Manager	Present for all	Present for all
Adam O’Keefe (AO) GUT - Project Manager	Present for all	Present for all
Gabriel Rogers (GR) NICE - Technical Adviser (HE)	Present for all	Present for all

Observer:	
Alice Biggane	Present for all on both days

Expert witnesses:	
Jenny Donovan, ProtecT trail investigator	Present for items 1-2 on day 1
Freddie Hamdy, ProtecT trail investigator	Present for items 1-2 on day 1

Apologies:
Abi Ademoyero - Committee member
Brian McGlynn – Committee member
Mark Robinson – Committee member
Sue Spiers – GUT – Associate Director

Day 1 Tuesday 10 July 2018:

1. Welcome, apologies, minutes of the last meeting, declarations of interest
<p>The Chair welcomed the Committee members and attendees to the day 1 of the seventh meeting on Prostate cancer. Apologies for the meeting were received as detailed above.</p> <p>The minutes of the previous meeting were agreed as an accurate record.</p> <p>Each committee member was asked to declare any new conflicts since the previous meeting. No new interests were declared. The Chair advised that, as authors of the ProtecT trial, HK and JO were unable to participate in the drafting of recommendation or Review Question 2, but could otherwise fully participate. The Chair confirmed that, having reviewed the historical declaration of interests table that the remaining committee members present were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.</p>
2. Expert witness testimony – Jenny Donovan and Freddie Hamdy, ProtecT trial
<p>Professors Donovan and Hamdy provided expert testimony from the ProtecT trial for the consideration of the committee. Committee members were then given the opportunity to ask Profs Donovan and Hamdy questions related to their testimony.</p>
3. Review Question 2 What is the clinical and cost- effectiveness of active surveillance, radical prostatectomy or radical radiotherapy compared to each other for people with localised prostate cancer?
<p>CD recapped the search protocol and presented the clinical evidence supporting Review Question 2 for the committee’s consideration. FC then presented the health economic evidence identified for this question.</p> <p>The committee considered the evidence presented, drafted one new recommendation and stood down one recommendation.</p>
4. Next steps

The Chair thanked the committee for their input and confirmed day 2 would commence at 9am as scheduled.

Day 2 Wednesday 11 July 2018:

1. Welcome, apologies, declarations of interest

The Chair welcomed the Committee members and attendees to day two of the seventh meeting of the prostate cancer guideline committee. Apologies for the meeting were received as detailed above.

Each committee member was asked to any new conflicts. No new interests were declared. The Chair confirmed that the committee members present were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

2. Review Question 3 Which of the following, alone or in combination, constitutes the most clinical and cost- effective pathway for excluding the clinically significant progression of prostate cancer in people with low to intermediate risk (as defined in NICE CG175): Multiparametric/ functional MRI, TRUS biopsy, Transperineal template biopsy?

JB presented additional evidence supporting Review Question 3 following the committee's request to amend the review protocol.

The committee reviewed the draft recommendations in light of the newly identified evidence and: drafted two new recommendations, updated an existing recommendation and drafted two research recommendations.

3. Review Question 8 What is the most clinically- and cost-effective follow-up protocol for people who have a raised PSA, negative MRI and/ or negative biopsy?

JB recapped the search protocol and presented the clinical evidence supporting Review Question 8 for the committee's consideration. JB advised the committee that recommendations for this question would be drafted following the presentation of the health economic evidence at the next meeting.

4. HE model update

FC and GR discussed developments with the health economic model being constructed with the committee and checked with it that assumptions being made were reasonable.

5. Next steps

The Chair confirmed the venue, date and time of the next meeting, as detailed below and thanked the Committee and others present for their contribution to the meeting before closing the meeting.

Date of next meeting:

11 / 12 September 2018

Location of next meeting: NICE - Manchester